Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 8.19
(2.12%)
SEK 8.19
(2.12%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -82.08 Million SEK | 26.49% |
| 2023 | -111.66 Million SEK | 6.76% |
| 2022 | -119.76 Million SEK | 14.07% |
| 2021 | -139.37 Million SEK | -138.79% |
| 2020 | -58.36 Million SEK | -59.03% |
| 2019 | -36.7 Million SEK | -160.72% |
| 2018 | -14.07 Million SEK | 74.72% |
| 2017 | -55.69 Million SEK | -110.99% |
| 2016 | -26.39 Million SEK | -57.79% |
| 2015 | -16.72 Million SEK | 32.31% |
| 2014 | -24.71 Million SEK | 62.28% |
| 2013 | -65.51 Million SEK | 60.13% |
| 2012 | -164.34 Million SEK | -4.16% |
| 2011 | -157.78 Million SEK | 68.53% |
| 2010 | -501.33 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -91.45 Million SEK | 19.06% |
| 2024 Q4 | -82.08 Million SEK | 10.25% |
| 2024 Q1 | -152.57 Million SEK | -36.63% |
| 2024 Q2 | -113 Million SEK | 25.94% |
| 2023 Q1 | -130.92 Million SEK | -9.32% |
| 2023 Q4 | -111.66 Million SEK | -44.44% |
| 2023 Q3 | -77.31 Million SEK | 23.91% |
| 2023 FY | -111.66 Million SEK | 6.76% |
| 2023 Q2 | -101.6 Million SEK | 22.39% |
| 2022 Q2 | -208.39 Million SEK | 5.56% |
| 2022 Q4 | -119.76 Million SEK | 21.66% |
| 2022 Q1 | -220.65 Million SEK | -58.32% |
| 2022 FY | -119.76 Million SEK | 14.07% |
| 2022 Q3 | -152.86 Million SEK | 26.65% |
| 2021 Q3 | -154.18 Million SEK | -22.91% |
| 2021 Q2 | -125.44 Million SEK | 12.31% |
| 2021 Q4 | -139.37 Million SEK | 9.61% |
| 2021 Q1 | -143.05 Million SEK | -145.1% |
| 2021 FY | -139.37 Million SEK | -138.79% |
| 2020 Q1 | -50.58 Million SEK | -37.82% |
| 2020 FY | -58.36 Million SEK | -59.03% |
| 2020 Q2 | -88.27 Million SEK | -74.51% |
| 2020 Q3 | -51.53 Million SEK | 41.62% |
| 2020 Q4 | -58.36 Million SEK | -13.26% |
| 2019 Q2 | -39.52 Million SEK | -81.71% |
| 2019 FY | -36.7 Million SEK | -160.72% |
| 2019 Q4 | -36.7 Million SEK | -20.4% |
| 2019 Q3 | -30.48 Million SEK | 22.87% |
| 2019 Q1 | -21.75 Million SEK | -54.51% |
| 2018 Q2 | -32.58 Million SEK | 25.36% |
| 2018 Q4 | -14.07 Million SEK | 57.08% |
| 2018 Q3 | -32.79 Million SEK | -0.64% |
| 2018 Q1 | -43.65 Million SEK | 21.61% |
| 2018 FY | -14.07 Million SEK | 74.72% |
| 2017 Q3 | -12.21 Million SEK | 40.58% |
| 2017 Q2 | -20.55 Million SEK | 22.21% |
| 2017 Q4 | -55.69 Million SEK | -355.98% |
| 2017 FY | -55.69 Million SEK | -110.99% |
| 2017 Q1 | -26.42 Million SEK | -0.1% |
| 2016 Q1 | -10.87 Million SEK | 34.97% |
| 2016 FY | -26.39 Million SEK | -57.79% |
| 2016 Q3 | -31.49 Million SEK | -203.77% |
| 2016 Q4 | -26.39 Million SEK | 16.18% |
| 2016 Q2 | -10.36 Million SEK | 4.71% |
| 2015 Q1 | -21.81 Million SEK | 11.73% |
| 2015 FY | -16.72 Million SEK | 32.31% |
| 2015 Q3 | -26.21 Million SEK | -1.29% |
| 2015 Q4 | -16.72 Million SEK | 36.18% |
| 2015 Q2 | -25.88 Million SEK | -18.62% |
| 2014 Q2 | -37.96 Million SEK | 7.62% |
| 2014 Q1 | -41.09 Million SEK | 37.28% |
| 2014 Q4 | -24.71 Million SEK | 11.11% |
| 2014 FY | -24.71 Million SEK | 62.28% |
| 2014 Q3 | -27.8 Million SEK | 26.76% |
| 2013 Q3 | -38.32 Million SEK | 0.0% |
| 2013 Q4 | -65.51 Million SEK | -70.94% |
| 2013 FY | -65.51 Million SEK | 60.13% |
| 2013 Q1 | 21.96 Million SEK | 113.36% |
| 2012 Q1 | -155.87 Million SEK | 1.21% |
| 2012 FY | -164.34 Million SEK | -4.16% |
| 2012 Q3 | -173.33 Million SEK | 1.81% |
| 2012 Q2 | -176.52 Million SEK | -13.25% |
| 2012 Q4 | -164.34 Million SEK | 5.19% |
| 2011 Q2 | -473.63 Million SEK | 0.0% |
| 2011 FY | -157.78 Million SEK | 68.53% |
| 2011 Q3 | -441.54 Million SEK | 6.77% |
| 2011 Q4 | -157.78 Million SEK | 64.27% |
| 2010 FY | -501.33 Million SEK | 0.0% |
| 2010 Q4 | -501.33 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| NextCell Pharma AB | -46.79 Million SEK | -75.433% |
| Biovica International AB (publ) | -58.73 Million SEK | -39.752% |
| Abliva AB (publ) | -57.24 Million SEK | -43.407% |
| Active Biotech AB (publ) | -33.2 Million SEK | -147.247% |
| Aptahem AB (publ) | 2.9 Million SEK | 2922.142% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -64.103% |
| BioInvent International AB (publ) | -236.3 Million SEK | 65.263% |
| BioArctic AB (publ) | -606.58 Million SEK | 86.468% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -108.435% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1620.111% |
| Cantargia AB (publ) | -139.74 Million SEK | 41.261% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -8793.391% |
| CombiGene AB (publ) | -101.44 Million SEK | 19.079% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 57.84% |
| Fluicell AB (publ) | -2.76 Million SEK | -2870.901% |
| Genovis AB (publ.) | -43.94 Million SEK | -86.81% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 160.936% |
| Mendus AB (publ) | -96.29 Million SEK | 14.755% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 0.141% |
| LIDDS AB (publ) | -13.51 Million SEK | -507.504% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 500.224% |
| Saniona AB (publ) | 40.44 Million SEK | 302.947% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -81.538% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -64.389% |
| Xintela AB (publ) | -7.8 Million SEK | -951.172% |
| Amniotics AB (publ) | -5.63 Million SEK | -1357.493% |
| Corline Biomedical AB | -17.01 Million SEK | -382.518% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -179.366% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 75.055% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 1.979% |
| Intervacc AB (publ) | -88.16 Million SEK | 6.89% |
| Kancera AB (publ) | -45.69 Million SEK | -79.651% |
| Lipum AB (publ) | -8.46 Million SEK | -869.711% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -157.105% |
| Nanologica AB (publ) | -9.38 Million SEK | -774.372% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 75.395% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 149.426% |
| AcouSort AB (publ) | -23.98 Million SEK | -242.225% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -46.881% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 254.23% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -330.672% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 36.611% |
| Simris Alg AB (publ) | 85.07 Million SEK | 196.487% |
| Ziccum AB (publ) | -2.13 Million SEK | -3741.179% |
| SynAct Pharma AB | -61.75 Million SEK | -32.916% |
| OncoZenge AB (publ) | -12.62 Million SEK | -550.083% |
| Camurus AB (publ) | -1.16 Billion SEK | 92.956% |
| 2cureX AB (publ) | -13.4 Million SEK | -512.445% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -3698.519% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 40.581% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -520.492% |
| I-Tech AB | -83.26 Million SEK | 1.412% |
| Cyxone AB (publ) | -16.67 Million SEK | -392.418% |
| Biosergen AB | -1.88 Million SEK | -4259.32% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -283.311% |
| Alzinova AB (publ) | -21.22 Million SEK | -286.724% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -22.663% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 1.976% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1484.39% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -294.777% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -2661.978% |